Anthrax

$3.5M grant from U.S. government used for drug to treat anthrax exposure

Published in Blood Weekly, October 30th, 2003

Elusys Therapeutics, Inc., has received an additional $3.5 million from the U.S. Department of Defense for the further development of its drug to remove anthrax toxin from the bloodstream.

"The support from the Department of Defense allows us to make development of our unique anthrax drug, ETI-205, a top priority," said Stephen Sudovar, president and CEO of Elusys. "This funding enables us to complete the last phases of our efficacy studies and to scale up production in preparation for human safety studies."

Elusys is developing a heteropolymer (HP) drug to remove anthrax toxin from the bloodstream. "The toxin is the component of anthrax that can...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-10-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry